Literature DB >> 21838519

The utilization and outcome of diagnostic, predictive, and prenatal genetic testing for huntington disease in johannesburg, South Africa.

Elaine B Sizer1, Tabitha Haw, Tina-Marié Wessels, Jennifer G R Kromberg, Amanda Krause.   

Abstract

BACKGROUND: Huntington disease (HD) is an autosomal dominant neurodegenerative disorder for which genetic counseling and testing are available in South Africa.
OBJECTIVE: The purpose of this study was to assess the utilization of the services available in Johannesburg for diagnostic, predictive, and prenatal genetic testing and counseling for HD and the characteristics of the patients who use them. SUBJECTS AND METHODS: A retrospective study was conducted using records of patients (n=287) who had genetic counseling and/or testing for HD through the Division of Human Genetics, National Health Laboratory Service and University of the Witwatersrand, Johannesburg, between January 1998 and December 2006. Age, gender, number of children, ethnicity, and test results were analyzed.
RESULTS: Of the 287 patients included in this study, 77% had diagnostic testing, 20% predictive, and 3% prenatal testing. In the diagnostic group, 47% of subjects tested positive for HD1 and 9% for HDL2 (all Black or of mixed ancestry). Altogether, 66.7% of subjects in the predictive group had testing and 39.5% were positive. In both groups, White subjects were overrepresented. In seven prenatal tests, three fetuses (including a set of twins) tested positive for HD and termination of pregnancy was requested. DISCUSSION AND
CONCLUSION: The HD services for predictive and prenatal testing appear to be underutilized, especially by Black individuals, possibly because of lack of awareness among these individuals and among healthcare providers and/or a lower HD prevalence in this group. Recognition of and testing for HDL2 is important in South Africa's large Black population, and HD testing services cannot be considered complete unless testing for both HD1 and HDL2 are undertaken.

Entities:  

Mesh:

Year:  2011        PMID: 21838519     DOI: 10.1089/gtmb.2011.0007

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  11 in total

1.  The Spectrum of Caregiving in Palliative Care for Serious, Advanced, Rare Diseases: Key Issues and Research Directions.

Authors:  Lynn S Adams; Jeri L Miller; Patricia A Grady
Journal:  J Palliat Med       Date:  2016-06-01       Impact factor: 2.947

2.  Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Authors:  K A Quaid; S W Eberly; E Kayson-Rubin; D Oakes; I Shoulson
Journal:  Clin Genet       Date:  2016-11-24       Impact factor: 4.438

3.  Analysis of the Reasons for Non-Uptake of Predictive Testing for Huntington's Disease in Spain: A Qualitative Study.

Authors:  Jesús Rivera-Navarro; Esther Cubo; Natividad Mariscal
Journal:  J Genet Couns       Date:  2015-04-30       Impact factor: 2.537

4.  The Changing Age of Individuals Seeking Presymptomatic Genetic Testing for Huntington Disease.

Authors:  Melissa A Holman; John Quillin; Timothy P York; Claudia M Testa; Ami R Rosen; Virginia W Norris
Journal:  J Genet Couns       Date:  2018-02-20       Impact factor: 2.537

5.  Huntington disease: who seeks presymptomatic genetic testing, why and what are the outcomes?

Authors:  Tracey M Scuffham; John C MacMillan
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

6.  Prenatal testing in Huntington disease: after the test, choices recommence.

Authors:  Hanane Bouchghoul; Stéphane-Françoise Clément; Danièle Vauthier; Cécile Cazeneuve; Sandrine Noel; Marc Dommergues; Delphine Héron; Jacky Nizard; Marcela Gargiulo; Alexandra Durr
Journal:  Eur J Hum Genet       Date:  2016-06-15       Impact factor: 4.246

7.  Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.

Authors:  Amanda Krause; Claire Mitchell; Fahmida Essop; Susan Tager; James Temlett; Giovanni Stevanin; Christopher Ross; Dobrila Rudnicki; Russell Margolis
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-06-16       Impact factor: 3.568

Review 8.  A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Authors:  Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams
Journal:  Prog Neurobiol       Date:  2013-09-11       Impact factor: 11.685

9.  Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes.

Authors:  Fiona K Baine; Chris Kay; Maria E Ketelaar; Jennifer A Collins; Alicia Semaka; Crystal N Doty; Amanda Krause; L Jacquie Greenberg; Michael R Hayden
Journal:  Eur J Hum Genet       Date:  2013-03-06       Impact factor: 4.246

10.  Progressive and self-limiting neurodegenerative disorders in Africa: a new prominent field of research led by South Africa but without strong health policy.

Authors:  Brice Poreau
Journal:  Pan Afr Med J       Date:  2016-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.